AstraZeneca, Sage Bionetworks Partner on Cancer Therapeutic Development

The deal combines Sage's expertise in computer models of disease genetics with AstraZeneca's expertise in oncology, as well as access to the drug manufacturer's compounds, to investigate regulatory pathways common in different cancers.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.